TY - JOUR
T1 - Practical Management of Oligometastatic Non–Small-Cell Lung Cancer
AU - Jasper, Katie
AU - Stiles, Brendon
AU - McDonald, Fiona
AU - Palma, David A.
N1 - Publisher Copyright:
Copyright © 2022 American Society of Clinical Oncology. All rights reserved.
PY - 2022/2/20
Y1 - 2022/2/20
N2 - Local ablative therapies, including surgery or stereotactic radiotherapy (SABR), are becoming an integral component in the treatment of oligometastatic disease in non–small-cell lung cancer. In this review, we summarize recent randomized evidence supporting progression-free survival and overall survival benefits of local ablation in these patients, as well as upcoming phase III data which should help us better understand the ideal treatment conditions and provide more insight into the oligometastatic state. Since practical management of oligometastatic disease in non–small-cell lung cancer can be challenging, we discuss a modern framework to identify patient, tumor, and treatment characteristics that can best guide management.
AB - Local ablative therapies, including surgery or stereotactic radiotherapy (SABR), are becoming an integral component in the treatment of oligometastatic disease in non–small-cell lung cancer. In this review, we summarize recent randomized evidence supporting progression-free survival and overall survival benefits of local ablation in these patients, as well as upcoming phase III data which should help us better understand the ideal treatment conditions and provide more insight into the oligometastatic state. Since practical management of oligometastatic disease in non–small-cell lung cancer can be challenging, we discuss a modern framework to identify patient, tumor, and treatment characteristics that can best guide management.
UR - http://www.scopus.com/inward/record.url?scp=85124809812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124809812&partnerID=8YFLogxK
U2 - 10.1200/JCO.21.01719
DO - 10.1200/JCO.21.01719
M3 - Review article
C2 - 34985915
AN - SCOPUS:85124809812
SN - 0732-183X
VL - 40
SP - 635
EP - 641
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -